Greenoaks and Sequoia lead $5bn Series C for Alphabet's AI drug designer Isomorphic
The London company has now raised more than $7.7 billion and is valued at an estimated $50 billion, though none of its drug candidates has yet entered the clinic.
By World Nexus Group Editorial
Isomorphic Labs, the London-based Alphabet spinout that applies AI to drug discovery, closed a $5 billion Series C on 17 November 2026. Greenoaks and Sequoia Capital led the round12.
The round and its backers
Alphabet made what Isomorphic called “continued significant investment”, and Andreessen Horowitz joined as a new investor12. Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also took part2. The round comes after a $2.1 billion Series B announced in May1. pharmaphorum puts Isomorphic's total funding since its 2021 founding at more than $7.7 billion and its paper value at an estimated $50 billion2.
Isomorphic said the money will go on three things: building and refining its foundational simulation models, advancing and scaling its internal and partnered pipeline of medicine candidates, and building global AI-led bioengineering infrastructure2. Its platform, IsoDDE, is a drug design engine built on a suite of simulation models that predict 3D protein structures and how they interact with drug candidates, model binding affinities and find new binding pockets2. The company says the platform is producing positive preclinical results in oncology and immunology, for its own programmes and for partners, “setting the stage for clinical entry”12.
Sir Demis Hassabis, who leads the company, said the round would help drive “our first therapeutic programmes towards clinical trials to deliver tangible impact for patients”2.
What it means for the market
The scale stands out against the rest of biotech venture funding. BioPharma Dive, which tracks financings for 26 firms, says Isomorphic's two rounds this year are the largest venture infusions in that group, and the $5 billion Series C is the biggest financing it has recorded since 20221. pharmaphorum says the deal puts 2026 on track to be a strong year for venture financing, while noting that Isomorphic accounts for the bulk of the total2. For investors, headline biotech funding figures for 2026 will therefore say more about one company than about the sector as a whole.
The raise also lands in a difficult moment for AI stocks more broadly. BioPharma Dive describes a reckoning across the AI industry and a wider sell-off in technology shares, yet Isomorphic's investors appear unfazed1. For now, a large AI drug discovery platform with established pharma partners has been able to raise capital on a record scale despite that backdrop1.
Those partners matter for corporate development teams. Isomorphic already counts Novartis, Johnson & Johnson and Eli Lilly among its partners12. Large drugmakers including Bristol Myers Squibb, Merck & Co., Lilly and Novo Nordisk have announced significant AI investments or partnerships this year1. For the UK, pharmaphorum calls the round a boost for the domestic biotech sector2.
Caveats
Isomorphic has yet to put any drug candidate into clinical trials2. There is no approved medicine designed by AI, and even supporters of the approach warn that it is unlikely to remove quickly the risks and failures of drug development1. The evidence the company cites is preclinical, and its next test is the move of its first programmes into the clinic12.
Sources
- 1AI drugmaker Isomorphic restocks with $5B fundraise · BioPharma Dive
- 2Isomorphic Labs raises $5bn in massive third round · pharmaphorum
This briefing summarises publicly available research and reporting for information only. It is not medical, investment or legal advice. Follow the sources listed for the primary research and reporting.